Black Diamond Therapeutics BDTX made its public debut Thursday morning, opening at $33 after being priced at $19 per share.
The company listed its shares on the Nasdaq under the ticker symbol "BDTX."
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule and tumor-agnostic therapies.
JPMorgan, Jefferies, and Cowen and company are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering.
Related links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
